MVCD2
MCID: MCR112
MIFTS: 42

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 57 73 12 38
Microvascular Complications of Diabetes, Susceptibility to, 2 57 28 5
Proliferative Diabetic Retinopathy 73 71
Diabetic Nephropathy 73 71
Mvcd2 57 73
Proliferative Retinopathy, Diabetic, Susceptibility to 57
End-Stage Renal Disease, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic 57
End-Stage Renal Disease, Diabetic 57
Diabetic End-Stage Renal Disease 73

Classifications:



External Ids:

OMIM® 57 612623
OMIM Phenotypic Series 57 PS603933
MeSH 43 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 2, also known as microvascular complications of diabetes, susceptibility to, 2, is related to microvascular complications of diabetes 3 and background diabetic retinopathy. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Mecobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and retina.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 646)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 11.7
2 background diabetic retinopathy 11.6
3 microvascular complications of diabetes 5 11.6
4 vitreoretinopathy, neovascular inflammatory 11.5
5 microvascular complications of diabetes 1 11.5
6 microvascular complications of diabetes 7 11.5
7 severe nonproliferative diabetic retinopathy 11.4
8 retinal detachment 11.2
9 macular retinal edema 11.1
10 renal fibrosis 11.1
11 macular holes 11.0
12 neovascular glaucoma 10.9
13 diabetic macular edema 10.9
14 glomerulonephritis 10.8
15 type 1 diabetes mellitus 10.8
16 vitreoretinopathy 10.8
17 nephrotic syndrome 10.7
18 retinal disease 10.7
19 type 2 diabetes mellitus 10.7
20 hypertension, essential 10.7
21 cataract 10.7
22 rubeosis iridis 10.7
23 intraocular pressure quantitative trait locus 10.7
24 retinal vascular disease 10.7
25 eye disease 10.7
26 diabetes mellitus 10.6
27 ceroid lipofuscinosis, neuronal, 5 10.6
28 retinal ischemia 10.6
29 uremia 10.6
30 iga glomerulonephritis 10.6
31 iga nephropathy 1 10.6
32 vitreous detachment 10.6
33 membranous nephropathy 10.6
34 microvascular complications of diabetes 4 10.6
35 microvascular complications of diabetes 6 10.6
36 retinal perforation 10.6
37 mckusick-kaufman syndrome 10.5
38 hyperglycemia 10.5
39 oto-palatal-digital syndrome 10.5
40 kidney hypertrophy 10.5
41 endophthalmitis 10.5
42 glomerular disease 10.5
43 lipoid nephrosis 10.5
44 uveitis 10.5
45 focal segmental glomerulosclerosis 10.5
46 glucose intolerance 10.5
47 embryonal rhabdomyosarcoma 10.5
48 hyperinsulinism 10.4
49 nephrosclerosis 10.4
50 retinal vein occlusion 10.4

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM®:

612623 (Updated 08-Dec-2022)

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
3
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
4
Captopril Approved Phase 4 62571-86-2 44093
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
7
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
8
Dipivefrin Approved Phase 4 52365-63-6 3105
9
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Atenolol Approved Phase 4 29122-68-7 2249
12
Doxazosin Approved Phase 4 74191-85-8 3157
13
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
14
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
15
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
16
Simvastatin Approved Phase 4 79902-63-9 54454
17
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
18
Insulin glulisine Approved Phase 4 207748-29-6
19
Insulin glargine Approved Phase 4 160337-95-1 118984454
20
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
21
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
22
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
23
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
26
Carbamide peroxide Approved Phase 4 124-43-6
27
Candesartan cilexetil Approved Phase 4 145040-37-5
28
Allopurinol Approved Phase 4 315-30-0 2094 135401907
29
Nisoldipine Approved Phase 4 63675-72-9 4499
30
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
31
Probucol Approved, Investigational Phase 4 23288-49-5 4912
32
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
33
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
34
Atorvastatin Approved Phase 4 134523-00-5 60823
35
Indapamide Approved Phase 4 26807-65-8 3702
36
Insulin lispro Approved Phase 4 133107-64-9 16132438
37
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
38
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
39
Trandolapril Approved Phase 4 87679-37-6 5484727
40
Saxagliptin Approved Phase 4 361442-04-8 11243969
41
Ranibizumab Approved Phase 4 347396-82-1
42 Grape Approved Phase 4
43
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
44
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
45
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
46
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
47
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020
48
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
49
Losartan Approved Phase 4 114798-26-4 3961
50
Valsartan Approved, Investigational Phase 4 137862-53-4 60846

Interventional clinical trials:

(show top 50) (show all 460)
# Name Status NCT ID Phase Drugs
1 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
2 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
4 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Unknown status NCT04464694 Phase 4 Ranibizumab
6 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
7 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
8 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Unknown status NCT04283162 Phase 4 Calcium Dobesilate
9 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
10 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
11 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
12 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
13 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
14 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
15 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
16 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
17 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
18 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
19 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
20 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
21 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Completed NCT02096874 Phase 4 Bevacizumab
22 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
23 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
24 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
25 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
26 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
27 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
28 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Completed NCT02874313 Phase 4 Pharmacological treatment
29 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
30 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
31 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
32 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
33 A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus Completed NCT02276196 Phase 4 Lixisenatide;Insulin glulisine
34 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
35 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
36 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Completed NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
37 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
38 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil 32mg
39 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
40 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
41 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
42 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
43 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
44 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
45 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
46 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
47 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
48 Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea Completed NCT02816762 Phase 4 Pharmacological treatment
49 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH
50 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 2 28 EPO

Anatomical Context for Microvascular Complications of Diabetes 2

Organs/tissues related to Microvascular Complications of Diabetes 2:

MalaCards : Kidney, Endothelial, Retina, Eye, Pancreas, Bone Marrow, Heart

Publications for Microvascular Complications of Diabetes 2

Articles related to Microvascular Complications of Diabetes 2:

(show top 50) (show all 25779)
# Title Authors PMID Year
1
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 62 57 5
18458324 2008
2
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. 62 57
16120858 2005
3
Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. 62
36254977 2023
4
Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. 62
36375645 2023
5
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. 62
36280016 2023
6
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence. 62
36341813 2023
7
Suppression of lncRNA Snhg1 inhibits high glucose-induced inflammation and proliferation in mouse mesangial cells. 62
36243327 2023
8
The changing trajectory of diabetic kidney disease. 62
36250469 2023
9
Ion channels and channelopathies in glomeruli. 62
36007181 2023
10
Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. 62
36270460 2023
11
The relationship between reduced choroidal thickness due to high plasma asymmetrical dimethylarginine level and increased severity of diabetic retinopathy. 62
35170653 2023
12
Modern indications for referral for kidney and pancreas transplantation. 62
36444661 2023
13
CircHOMER1 aggravates oxidative stress, inflammation and extracellular matrix deposition in high glucose-induced human mesangial cells. 62
36181383 2022
14
XIST silencing alleviated inflammation and mesangial cells proliferation in diabetic nephropathy by sponging miR-485. 62
32669002 2022
15
Comparison of functional changes of retina after subthreshold and threshold pan-retinal photocoagulation in severe non-proliferative diabetic retinopathy. 62
36070046 2022
16
The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases. 62
36331711 2022
17
Vitreous protein networks around ANG2 and VEGF in proliferative diabetic retinopathy and the differential effects of aflibercept versus bevacizumab pre-treatment. 62
36473885 2022
18
Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy. 62
36114830 2022
19
Challenges in the Clinical Management of Proliferative Diabetic Retinopathy: Treatment Choice and Follow-up. 62
36454587 2022
20
The Patient Experience with Diabetic Retinopathy: Qualitative Analysis of Patients with Proliferative Diabetic Retinopathy. 62
36460939 2022
21
Full-field and multifocal electroretinogram in non-diabetic controls and diabetics with and without retinopathy. 62
35661609 2022
22
Quantification of Macular Perfusion Following Panretinal Photocoagulation for Diabetic Retinopathy: An Optical Coherence Tomography Angiography Study. 62
36470406 2022
23
Association between cause of kidney failure and fracture incidence in a national US dialysis population cohort study. 62
36381373 2022
24
Changes in the spectrum of kidney diseases: a survey of 2803 patients from 2010 to 2018 at a single center in southeastern China. 62
35656734 2022
25
Kidney biopsy during pregnancy: a difficult decision. A case series reporting on 20 patients from Mexico. 62
35994230 2022
26
Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. 62
36185030 2022
27
The roles of MTHFR (C677T, A1298C) and MGP (G-7A, T-138C) gene variations in development of diabetic nephropathy in patients with type 2 diabetes mellitus. 62
36404848 2022
28
Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus. 62
35082227 2022
29
Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach. 62
36415625 2022
30
Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy. 62
36454552 2022
31
Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention. 62
35535500 2022
32
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial. 62
36451252 2022
33
Low expression of RBP4 in the vitreous humour of patients with proliferative diabetic retinopathy who underwent Conbercept intravitreal injection. 62
35932904 2022
34
Haptoglobin Genotype Does Not Confer a Risk of Stroke in Type 1 Diabetes. 62
36409784 2022
35
Expression of growth arrest specific 1 (Gas1) in the distal tubules and collecting ducts in normal kidney and in the early stages of diabetic nephropathy. 62
36272046 2022
36
Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis. 62
36375322 2022
37
Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms. 62
36404838 2022
38
Effect of Costus pictus per se and in combination with Metformin and Enalapril in streptozotocin induced diabetic nephropathy in rats. 62
36404856 2022
39
Renoprotective activity of anethole- rich fraction from aromatic herbs on junk food induced diabetic nephropathy in rats. 62
36404830 2022
40
Emerging drugs for the treatment of diabetic nephropathy. 62
36472144 2022
41
Verteporfin inhibits the dedifferentiation of tubular epithelial cells via TGF-β1/Smad pathway but induces podocyte loss in diabetic nephropathy. 62
36375573 2022
42
Statement of Retraction: Diminution of microRNA-98 alleviates renal fibrosis in diabetic nephropathy by elevating Nedd4L and inactivating TGF-β/Smad2/3 pathway. 62
36346834 2022
43
Natural swietenine attenuates diabetic nephropathy by regulating the NF-κB/NLRP3/Caspase-1 signaling pathways: In vivo and in vitro study. 62
36066211 2022
44
Effect of Acacia senegal on TGF-β1 and vascular mediators in a rat model of diabetic nephropathy. 62
32574082 2022
45
Kirenol alleviates diabetic nephropathy via regulating TGF-β/Smads and the NF-κB signal pathway. 62
36073930 2022
46
Association of the expression pattern and functions of long non-coding RNA with the progression of diabetic nephropathy. 62
35718604 2022
47
NUP160 knockdown inhibits the progression of diabetic nephropathy in vitro and in vivo. 62
35785044 2022
48
Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. 62
36314849 2022
49
NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. 62
36367498 2022
50
Blocking connexin 43 hemichannel-mediated ATP release reduces communication within and between tubular epithelial cells and medullary fibroblasts in a model of diabetic nephropathy. 62
36256487 2022

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EPO NM_000799.3(EPO):c.-1306C>A SNV Risk Factor
16602 rs1617640 GRCh37: 7:100317298-100317298
GRCh38: 7:100719675-100719675

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....